On November 4, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that Robert Wenham, M.D., Chair of the Gynecologic Oncology Program at Moffitt Cancer Center ("Moffitt") and principal investigator of Anixa’s ongoing Phase 1 clinical trial evaluating its novel CAR-T therapy for recurrent ovarian cancer, will present at the ESMO (Free ESMO Whitepaper) (European Society of Medical Oncology) Immuno-Oncology & Advanced Therapies Congress 2026, being held December 14–16, 2026, in London.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Wenham’s presentation, titled "Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer," will take place on Monday, December 14, 2026.

Anixa’s Phase 1, dose-escalating clinical trial (ClinicalTrials.gov NCT05316129), conducted at Moffitt, is evaluating the safety, tolerability, and preliminary signs of efficacy of liraltagene autoleucel, or lira-cel, a novel CAR-T therapy targeting the follicle-stimulating hormone receptor (FSHR), which is expressed on ovarian cancer cells but has limited expression in healthy tissues.

The Company recently announced completion of treatment of the fifth cohort in the trial, in which patients received 1×10⁷ CAR-positive cells per kilogram of body weight following lymphodepletion, representing a 100-fold increase over the dose administered to the first patient in the study. Following routine safety verification, the Company anticipates advancing to a sixth cohort at a dose of 1×10⁸ CAR-positive cells/kg, representing a 1,000-fold increase over the initial dose of 1×10⁵ CAR-positive cells/kg.

To date, no dose-limiting toxicities have been observed in the study. The Company has also reported encouraging preliminary clinical observations, including the first patient exhibiting stable disease 90 days following treatment and four patients surviving more than one year after treatment, including one patient who has survived beyond two years.

"We are pleased that Dr. Wenham will be presenting our ovarian cancer CAR-T clinical program at this important international immuno-oncology conference," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "Our trial continues to advance through progressively higher dose levels as well as lymphodepletion, and we are encouraged by the safety profile and preliminary clinical observations reported to date. The completion of our fifth cohort represents another important step in evaluating this novel approach to treating recurrent ovarian cancer. We look forward to sharing our progress with the international oncology community as we continue working with our colleagues at Moffitt to advance this promising therapy."

The ESMO (Free ESMO Whitepaper) Immuno-Oncology & Advanced Therapies Congress brings together leading researchers, clinicians, and oncology experts from around the world to discuss advances in cancer immunotherapy and emerging therapeutic approaches. The international meeting focuses on the latest scientific and clinical developments in immuno-oncology, including cellular therapies, novel immune-targeting strategies, and the challenges of extending the benefits of immunotherapy to a broader range of cancers.

(Press release, Anixa Biosciences, NOV 4, 2026, View Source;advanced-therapies-congress-2026-302928923.html [SID1234674222])